文献速递肿瘤 PET/CT

68Ga-THP PSMA PET/CT 在高危初治或生化复发前列腺癌中的安全性及治疗管理改变:PRONOUNCED II 期研究

A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study.
PubMed 文献 · J Nucl Med · 2021-12-01

结果显示无严重不良事件,2 例出现与药物相关的不良事件(瘙痒和静脉导管部位皮疹);42.9% 的患者因 PET/CT 结果改变了治疗管理(A 组 30%、B 组 42.9%、C 组 75%)。

要点

  • 68Ga-THP PSMA PET/CT 安全性良好,未发生严重不良事件或导致退出的不良事件。
  • 42.9% 的患者因 PET/CT 结果改变了预设治疗管理,C 组改变比例最高(75%)。
  • 该结果为计划开展的 III 期研究提供了依据。

核心结论

  • 68Ga-THP PSMA 使用安全,无严重不良事件,也无导致退出研究的不良事件。
  • 68Ga-THP PSMA PET/CT 改变了 42.9% 研究人群的治疗管理,与其他 PSMA 示踪剂研究相当。

研究设计与样本

  • A 组为高危未治疗前列腺癌(Gleason 评分 ≥ 4+3,或 PSA > 20 ng/mL,或临床分期 > T2c),共 20 例。
  • B 组为根治性前列腺切除后生化复发且适合挽救治疗(间隔 3 个月连续 2 次 PSA 升高且最终 PSA > 0.1 ng/mL,或 PSA ≥ 0.5 ng/mL),共 21 例。
  • C 组为根治性放疗或近距离治疗后至少 3 个月生化复发(PSA 较放疗或近距离治疗后最低值升高 > 2.0 ng/mL),共 8 例。
  • 静脉注射 160 ± 30 MBq 68Ga-THP PSMA 后 60 分钟行 PET/CT 显像。

主要发现

  • 无患者发生严重不良事件、因不良事件退出研究或死亡。
  • 2 例出现归因于 68Ga-THP PSMA 的治疗中出现的不良事件(1 例瘙痒,1 例静脉导管部位皮疹)。
  • 42.9% 的患者因 PET/CT 结果改变治疗管理:A 组 30%、B 组 42.9%、C 组 75%。

关键数值与推荐

  • 安全性通过生命体征、心血管指标、血清血液学、生化、尿液分析、PSA 和不良事件评估。
  • 治疗管理改变定义为因 68Ga-THP PSMA PET/CT 结果而改变预设临床管理。

临床怎么用

  • 68Ga-THP PSMA PET/CT 可用于指导高危初治或生化复发前列腺癌患者的治疗管理决策。
  • 该示踪剂安全性良好,可作为 PSMA PET/CT 的备选方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objectives were to assess the safety and clinical impact of a novel, kit-based formulation of 68Ga-tris(hydroxypyridinone) (68Ga-THP) prostate-specific membrane antigen (PSMA) for PET/CT in guiding the management of patients with prostate cancer. Methods: Patients were prospectively recruited to group A (high-risk untreated prostate cancer; Gleason score ≥ 4 + 3, or prostate-specific antigen (PSA) level > 20 ng/mL or clinical stage > T2c), group B (biochemical recurrence and eligible for salvage treatment after radical prostatectomy with 2 consecutive rises in PSA with a 3-mo interval between reads and a final PSA level > 0.1 ng/mL or a PSA level ≥ 0.5 ng/mL), or group C (biochemical recurrence with radical curative radiotherapy or brachytherapy at least 3 mo before enrollment, and an increase in PSA level > 2.0 ng/mL above the nadir level after radiotherapy or brachytherapy). Patients underwent evaluation with PET/CT 60 min after intravenous administration of 160 ± 30 MBq of 68Ga-THP PSMA. Safety was assessed through vital signs, cardiovascular profile, serum hematology, biochemistry, urinalysis, PSA, and adverse events (AEs). A change in management was reported when the predefined clinical management of the patient was altered as a result of the 68Ga-THP PSMA PET/CT findings. Results: Forty-nine patients were evaluated with PET/CT: 20 in group A, 21 in group B, and 8 in group C. No patients experienced serious AEs, discontinued the study because of AEs, or died during the study. Two patients had treatment-emergent AEs attributed to 68Ga-THP PSMA (pruritus in one patient and a rash at the intravenous catheter site in another). A management change secondary to the PET/CT findings occurred in 42.9% of all patients: 30% in group A, 42.9% in group B, and 75% in group C. Conclusion: 68Ga-THP PSMA was safe to use, with no serious AEs and no AEs resulting in withdrawal from the study. 68Ga-THP PSMA PET/CT changed the management of 42.9% of the study population, comparable to studies using other PSMA tracers. These data form the basis of a planned phase III study of 68Ga-THP PSMA in patients with prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Afaq A, Payne H, Davda R, et al. A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study. J Nucl Med. 2021. PMID: 33741648. doi:10.2967/jnumed.120.257527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。